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Noninvasive prenatal diagnosisCurrent monitoring of fetal development includes fetal ultrasonography, chorionic villus sampling or amnio-
centesis for chromosome analysis, and maternal serum biochemical screening for analytes associated with
aneuploidy and open neural tube defects. Over the last 15 years, signiﬁcant advances in noninvasive prenatal
diagnosis (NIPD) via cell-free fetal (cff) nucleic acids in maternal plasma have resulted in the ability to deter-
mine fetal sex, RhD genotype, and aneuploidy. Cff nucleic acids in the maternal circulation originate primarily
from the placenta. This contrasts with cff nucleic acids in amniotic ﬂuid, which derive from the fetus, and are
present in signiﬁcantly higher concentrations than in maternal blood. The fetal origin of cff nucleic acids in
the amniotic ﬂuid permits the acquisition of real-time information about fetal development and gene expres-
sion. This review seeks to provide a comprehensive summary of the molecular analysis of cff nucleic acids in
maternal bioﬂuids to elucidate mechanisms of fetal development, physiology, and pathology. This article is
part of a Special Issue entitled: Molecular Genetics of Human Reproductive Failure.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Non-invasive monitoring of fetal development in vivo typically
consists of measurement of fundal height, anatomic evaluation by
fetal ultrasonography, and maternal serum biochemical screening
[1]. Genetic analysis of amniotic ﬂuid components or placental tissue
obtained via chorionic villus sampling has traditionally been utilized
for prenatal diagnosis. The disadvantage of these current invasive
methods for prenatal diagnosis is the risk of fetal loss. The pursuit of
safe and non-invasive prenatal diagnosis has been the focus of
many investigators over the last 15 years.
Cell-free fetal DNA (cffDNA) in the serum and plasma of pregnant
women was ﬁrst described in 1997 [2]. CffDNA has also been demon-
strated in other maternal bioﬂuids, including urine, cerebrospinal
ﬂuid (CSF), and peritoneal ﬂuid [3–6]. Recently, investigators have
begun to utilize new techniques to mine the previously discarded
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l rights reserved.development and global gene expression. Signiﬁcantly larger quanti-
ties of cffDNA are present in amniotic ﬂuid than in maternal serum
[7]. Recent investigations of cffmRNA in amniotic ﬂuid have sug-
gested that fetal nucleic acids present in amniotic ﬂuid can provide
real-time information about fetal disease, physiology, and develop-
ment [8–12]. This review seeks to provide a comprehensive summary
of discoveries over the last 15 years that have increased our under-
standing of fetal development, physiology, and pathology through
analysis of maternal bioﬂuids. We also examine the present and
future clinical applications for prenatal diagnosis of genetic disorders
and detection of normal and pathological fetal development via
maternal bioﬂuids.2. Fetal nucleic acids in maternal plasma, serum, and whole blood
2.1. Intact fetal cells
The isolation of intact fetal nucleated cells frommaternal blood for
prenatal diagnosis has been extensively studied [13]. Unfortunately,
this approach has limited clinical utility due to the low number of
fetal cells found in maternal circulation (approximately 1 fetal cell/
mL of maternal blood in euploid fetuses), which results in low sensi-
tivity, speciﬁcity, and reproducibility [14]. A multicenter trial spon-
sored by NIH reported a 41% sensitivity for detection of male fetal
cells in maternal blood, and a 74% detection rate for aneuploidy;
false-positive rates were 11% for fetal sex and 0.6–4% for aneuploidy
[15]. Thus, alternative approaches to prenatal diagnosis through
analysis of maternal blood were sought. Fig. 1 depicts a timeline of
key discoveries in this ﬁeld.
Fig. 1. Timeline of major discoveries involving fetal nucleic acids in maternal blood.
1971A.G. Edlow, D.W. Bianchi / Biochimica et Biophysica Acta 1822 (2012) 1970–19802.2. Cell-free fetal DNA (cffDNA)
The discovery of cffDNA in the maternal circulation was prompted
by the presence of tumor-associated oncogene mutations and micro-
satellite alterations in the plasma and serum DNA of women with
cancer [16]. Inspired by this work, Lo et al. hypothesized that a fetus
might also release cffDNA into the maternal circulation and demon-
strated the presence of male cffDNA sequences in the plasma and
serum of women carrying male fetuses [2]. Signiﬁcantly more fetal
DNA is present in the serum of pregnant women compared with
fetal DNA extracted from the cellular fraction of maternal blood
[17]. CffDNA in maternal plasma comprises approximately 10% of
the total cell-free DNA (range 3–19%) [18,19]. Cff nucleic acids are
stable in the maternal circulation, likely due to their association
with placenta-derived microparticles that protect them from nucle-
ase degradation [11,20–22]. CffDNA increases as gestation advances,
with a 21% weekly increase in the ﬁrst trimester [23], a slower rate
of rise in the second trimester, and a sharp increase during the last
eight weeks of pregnancy [18,24–28]. Cff DNA is rapidly cleared
from maternal circulation after delivery, with a half-life of approxi-
mately 16 min [29,30]. To maintain a steady state with such a short
half-life, fetal DNA must be liberated continuously in large quantities
into maternal circulation. Compared to analysis of intact fetal nucleat-
ed cells in maternal blood, which often requires the use of sophisti-
cated cell enrichment procedures, analysis of cffDNA in maternal
plasma and serum is rapid, reproducible, and possible to carry out
on a large scale. While cffDNA in maternal plasma is reported to be
stable at −20°C for ≥4 years [31], there are compelling data to sug-
gest that the duration of specimen storage may affect the concentra-
tion of cffDNA extracted from archived maternal serum. Lee et al.observed a degradation rate of −0.66 genome equivalents (GE)/mL
of cff DNA per month in samples frozen at −20 °C [32].
2.2.1. Tissue origin of fetal DNA
The placenta, fetal hematopoietic cells, and the fetus itself have all
been considered as possible sources of fetal DNA in the maternal cir-
culation [33]. CffDNA may be liberated into the maternal circulation
by destruction of fetal cells that have crossed the placenta. Terminal
UdTP nuclear end labeling (TUNEL) staining on fetal nucleated red
blood cells (NRBCs) conﬁrmed that 43% to 50% of fetal NRBCs undergo
apoptosis [34,35]. Additional studies suggested that fetal cells were
being destroyed in the maternal circulation, either by apoptosis
[34,36,37], or by another method of programmed cell death [38].
However, subsequent studies have called into question whether
fetal hematopoietic cells can account for the entire volume of cffDNA
in maternal plasma [39,40].
Physiologic and clinical data suggest that the majority of circulat-
ing nucleic acids are derived from the placenta, with some contribu-
tion from the fetal hematopoietic system. The discovery of cffDNA
in 80% of study subjects by day 28 post-conception implies that the
most likely source of cffDNA is the trophoblast, rather than fetal he-
matopoietic cells, given that the deﬁnitive fetoplacental circulation
is not established until days 28–30 post-conception [41]. Wataganara
et al. provided further evidence for the placental origin of cffDNA
when they found that cffDNA could be detected in maternal plasma
as long as 11 days after medical abortion, presumably because resid-
ual placental tissue continued to contribute to the pool of circulating
fetal DNA [23]. Detection of placental DNA in maternal plasma in
cases of conﬁned placental mosaicism further supports the placenta
as the primary origin of cffDNA in maternal circulation [42,43].
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maternal plasma [44]. Increased concentrations of cffDNA in maternal
plasma may reﬂect placental hypoxia and subsequent increased
apoptosis or necrosis of trophoblast [45].
2.3. Cell-free fetal mRNA (cffmRNA)
2.3.1. Characteristics and origin of cffmRNA in maternal plasma
Poon et al. demonstrated that mRNA transcribed from the Y chro-
mosome was detectable in the plasma of women carrying male fe-
tuses [46]. This discovery generated signiﬁcant excitement because
unlike cffDNA in maternal blood, cffmRNA is a gender-independent
nucleic acid marker. The detection of cffmRNA in maternal plasma
also does not depend on known paternal polymorphisms [47]. Plasma
cffmRNA is remarkably stable in peripheral blood [48], perhaps due to
its association with placenta-derived microparticles released from
cells via a variety of mechanisms, including apoptosis [11]. There is
some evidence that these microparticles protect cffDNA and cffmRNA
from nuclease degradation [21,22,33,49,50]. When plasma samples
from pregnant women were passed through a 0.45 μm ﬁlter, there
was a signiﬁcant decrease in human placental lactogen (hPL) and
beta human chorionic gonadotropin (ßhCG) mRNA, as well as mRNA
transcripts from the housekeeping gene GAPDH (glyceraldehyde 3-
phosphate dehydrogenase), providing further support for the hy-
pothesis that cffmRNA in maternal plasma is particle-bound [51].
Through ampliﬁcation of transcripts from two placental-speciﬁc
genes, ßhCG and hPL, the placenta was shown to be the major source
of fetal-derived RNA in maternal plasma [51]. The same study found
that there was no detectable hPLmRNA in umbilical cord plasma sam-
ples, suggesting a one-way transfer of hPL mRNA from the placenta
into the maternal circulation. Maternal plasma is preferable to mater-
nal whole blood for detection of placenta-derived mRNA [52,53]. Pla-
cental mRNA transcripts are detectable in maternal plasma by the
fourth week of gestation, with a median half-life of 14 min [54]. Like
cffDNA, cffmRNA transcripts are rapidly cleared from maternal
blood after delivery [48,54]. Fetal hematopoietic cells may also con-
tribute to the pool of cffmRNA [55,56]. A study comparing paired
newborn umbilical cord blood samples with antepartum and postpar-
tum maternal whole blood samples suggested that fetal (as opposed
to placental) transcripts may also contribute to cffmRNA in maternal
circulation [53].
Unlike cffDNA, total cffmRNA levels do not increase throughout
gestation. There appears to be an equilibrium of total cffmRNA that
does not change over time [47]. Several investigators have demon-
strated that individual levels of mRNA transcripts vary depending
on the trimester of pregnancy [51,57,58]. Invasive procedures,
which are known to transiently increase cffDNA levels, do not affect
mRNA levels [59].
2.3.2. Tracking fetal development through gene expression proﬁling
The systematic identiﬁcation of placental mRNA markers in ma-
ternal plasma through a microarray-based approach was described
in 2004 [60], paving the way for possible non-invasive gene expres-
sion proﬁling of the fetus through maternal plasma cffmRNA. Maron
et al. performed transcriptional analysis of maternal blood to identify
a set of biologically diverse fetal genes [53]. This gene expression mi-
croarray analysis compared whole blood mRNA transcripts common
to nine term pregnant women and their neonates (via umbilical
cord blood), but absent or signiﬁcantly reduced in postpartummater-
nal blood. They identiﬁed 71 genes in which the mRNA transcript was
involved in a developmental process, derived from fetal, placental, or
male tissue, associated with a physiological newborn response, or had
its expression limited to or highly associated with a fetus or neonate.
Twenty-seven developmental genes (neurodevelopmental genes
comprised 48% of these), ﬁve sensory perception genes (auditory, vi-
sual, olfactory), 22 genes involved in fetal physiologic function, and17 immune defense genes were identiﬁed. This transcriptional analy-
sis identiﬁed speciﬁc gene transcripts that appeared to be associated
with a fetus preparing to transition from the in utero environment
to extrauterine life.
2.3.3. Non-invasive detection of fetal aneuploidy
Circulating levels of cffmRNA have also been used in the noninva-
sive diagnosis of trisomy 21. Oudejans et al. were the ﬁrst to describe
a chromosome 21-speciﬁc mRNA present in maternal plasma (now
called C21orf105) [61]. They hypothesized that due to the direct
dosage-related difference in expression of chromosome 21-encoded
genes, quantiﬁcation of C21orf105 in maternal plasma could distin-
guish between trisomy 21 and euploid pregnancies. However, due
to large biological variation between and within individuals, and
the low expression proﬁle of C21orf105, quantiﬁcation initially
appeared unsuccessful [62–64]. In 2007, a placental-speciﬁc mRNA
sequence transcribed from a gene located on chromosome 21,
PLAC4, was identiﬁed via a microarray-based approach [65]. Allelic
ratios of placental-speciﬁc mRNA in maternal plasma were then uti-
lized to detect trisomy 21, with a diagnostic sensitivity of 90% and
speciﬁcity of 96.5% [65]. The same laboratory later used this placen-
tal RNA-SNP allelic ratio method to diagnose trisomy 18 [66], and
demonstrated that digital PCR can be used to detect fetal-derived
mRNA in maternal plasma. The placental RNA-SNP allelic ratio
method may also be theoretically applicable for diagnosis of trisomy
13 [67]. Although gender-independent, the RNA-SNP allelic ratio
method is still polymorphism-dependent, which is an important dis-
advantage. However, to address this limitation, other investigators
have described new placental mRNA target polymorphisms that
can be analyzed using the RNA-SNP allelic ratio methods [62]. One
marker panel has been described that has a combined heterozygos-
ity rate covering up to 95% of the US general population [49].
2.3.4. Detection of complications of pregnancy
CffmRNA may also be useful in diagnosing maternal complications
of pregnancy. Ng et al. demonstrated that corticotropin-releasing hor-
mone (CRH) mRNA levels were up to 10-fold higher in the plasma of
women with preeclampsia compared to normotensive controls [68].
These ﬁndings were subsequently conﬁrmed by several groups
[69–71]. While levels of CRH mRNA increase with increasing gesta-
tional age, levels of CRH mRNA have not been shown to correlate
with severity of preeclampsia [72]. One group found that CRH
mRNA levels are signiﬁcantly increased in the plasma of women
who subsequently develop preeclampsia, weeks before the onset of
clinical symptoms [69].
3. Fetal nucleic acids in amniotic ﬂuid
3.1. Cell-free fetal DNA
3.1.1. Origin
Large amounts of cffDNA were ﬁrst detected in amniotic ﬂuid in
2001 [7]. A study of 38 amniotic ﬂuid specimens collected for routine
indications at 16–20 weeks found that concentrations of cffDNA are
100- to 200-fold greater in amniotic ﬂuid compared to maternal plas-
ma [7]. Zhong et al. utilized real-time PCR ampliﬁcation to quantify
cffDNA in 12 matched maternal plasma and amniotic ﬂuid samples.
They found that concentrations of cffDNA were much higher (median
3978 copies/mL) in amniotic ﬂuid compared to maternal plasma
(median 96.6 copies/mL) [73].
CffDNA in amniotic ﬂuid originates from a separate pool than
cffDNA in maternal plasma and serum. While total cffDNA levels
were elevated in the serum of women carrying fetuses affected with
Down syndrome, cffDNA in the amniotic ﬂuid of two fetuses with tri-
somy 21 was not [7]. Makrydimas et al. investigated concentrations of
cffDNA in the fetal compared to maternal compartment. They found
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ﬂuid compared to maternal serum [74]. These investigators examined
relative cffDNA concentrations in the amniotic cavity, coelomic cavity,
and maternal serum in women undergoing elective ﬁrst-trimester
termination (7–9 weeks' gestation). They showed that cffDNA con-
centration was highest in the amniotic cavity and lowest in maternal
serum. In addition, they argued that the size of cffDNA in maternal
circulation (100–300 bp), made it unlikely that this DNA could diffuse
through the amniotic membrane into maternal circulation. Lun et al.
further developed the concept of separate pools of cffDNA in amniotic
ﬂuid and maternal serum through the use of a tissue-speciﬁc epige-
netic marker associated with the promoter region of the RAS associa-
tion family 1A (RASSF1A) gene [75]. RASSF1A is hypermethylated in
the placenta but hypomethylated in fetal tissues and in maternal
blood cells. By comparing cffDNA in 14 second-trimester amniotic
ﬂuid and maternal plasma samples, they found that hypermethylated
RASSF1A is 30-fold lower in amniotic ﬂuid than in maternal plasma,
suggesting that the placenta does not signiﬁcantly contribute to
cffDNA in amniotic ﬂuid.
While the origin of cffDNA in maternal plasma is likely placental,
cffDNA in amniotic ﬂuid likely originates directly from the fetus, via
shedding through urine, the trachea, fetal blood, or other mecha-
nisms. Thus, cffDNA may provide real-time information about fetal
development that cffDNA in maternal plasma cannot.
Recent improvements in cffDNA extraction methods improved the
yield of cffDNA from amniotic ﬂuid supernatant [76,77]. Gestational
age, storage time, and fetal karyotype all inﬂuence cffDNA fragmenta-
tion patterns [78,79]. Notably, the quantity and integrity of cffDNA is
signiﬁcantly lower in frozen than in fresh samples, and in aneuploid
than euploid samples, after adjusting for gestational age. No linear
relationship was observed between time in frozen storage and con-
centrations of cffDNA in amniotic ﬂuid [79]. Winter et al. found that
high-mobility group protein HMGA2, which is primarily expressed
by embryonic and fetal cells, is bound to cffDNA in amniotic ﬂuid.
This ﬁnding has signiﬁcance for improving the yield of cffDNA from
supernatant via immunoprecipitation techniques [80].
3.2. Cell-free fetal mRNA
3.2.1. Characteristics
Successful isolation of cffmRNA from amniotic ﬂuid has resulted in
discovery of new information about real-time fetal development and
physiology [8,81]. Larrabee et al. demonstrated, through ﬁltration of
centrifuged and uncentrifuged amniotic ﬂuid from a patient with
polyhydramnios, that cffmRNA in amniotic ﬂuid is particle-bound,
similar to cffmRNA in maternal plasma [82]. It is currently unknown
whether cffmRNA in amniotic ﬂuid plays a functional role, or whether
it is most useful as a reﬂection of functional development of fetal
tissues in direct contact with amniotic ﬂuid. Just as epigenetic studies
of cffDNA in amniotic ﬂuid demonstrate very little contribution from
the placenta [75], the limited detection of placental genes in gene
expression microarrays suggests that the placenta does not contribute
signiﬁcantly to cffmRNA in amniotic ﬂuid.
3.2.2. Gene expression analysis
Global gene expression analysis of cffmRNA in amniotic ﬂuid was
ﬁrst reported by Larrabee et al. in 2005 [8]. Amniotic ﬂuid was
obtained from women between 20 and 32 weeks of gestation under-
going therapeutic amnioreduction for polyhydramnios due to twin-
to-twin transfusion syndrome or hydrops fetalis. Four cases were
compared to a pooled second-trimester control sample. The mRNA
was then analyzed using Affymetrix U133A arrays. Statistically higher
expression of aquaporin-1, a gene involved in water transport, was
observed in fetuses with TTTS, suggesting that this gene may contrib-
ute to the amniotic ﬂuid imbalances noted in TTTS. The same study
also examined gene expression differences by gestational age, ﬁndingthat more surfactant genes were expressed at later gestational ages,
consistent with known patterns of fetal lung maturation. More
salivary and tracheobronchial gene transcripts were found at later
gestational ages, as well as fewer keratin gene transcripts, reﬂecting
epithelial maturation.
Hui et al. sought to determine which mRNA transcripts are ubiqui-
tously present in the amniotic ﬂuid supernatant of euploid fetuses in
the second trimester, in order to develop a normal second trimester
amniotic ﬂuid core transcriptome [83]. Ingenuity® Pathways Analysis
was utilized to infer the major physiologic functions and pathways
critical to mid-trimester human fetal development. Fetal organ spec-
iﬁcity was examined using the GNF Gene Expression Atlas as well as
manual literature searching. This investigation utilized gene expres-
sion data from 12 euploid second-trimester amniotic ﬂuid samples.
Four hundred seventy well-annotated genes were present in 12/12
samples. Twenty-three highly organ-speciﬁc transcripts were identi-
ﬁed; one-third of these were expressed by the fetal brain. Putative
organ sources of cffmRNA included the brain, spinal cord, lung, pan-
creas, liver, tongue, blood, heart, and kidney. These ﬁndings imply
that a fetal gene expression panel to evaluate normal organ system
function is feasible.
A recent proof-of-concept study sought to assess fetal functional
gene expression in amniotic ﬂuid supernatant obtained from 19 eu-
ploid fetuses in the second trimester, utilizing standardized NanoAr-
ray PCR (SNAP) [84]. SNAP uses internal standard (IS) sequences to
measure relative abundance of a gene transcript. Statistically signiﬁ-
cant differences in gene expression as a function of advancing gesta-
tional age and fetal gender were noted, suggesting that SNAP and
other transcriptomic analyses hold great potential for understanding
fetal development in real time.
3.2.3. Differential gene expression in aneuploid fetuses
In 2009, a functional genomic approachwas utilized to study the de-
velopment of fetuses with Down syndrome [81]. This study compared
gene expression in fetuses with trisomy 21 to those with normal chro-
mosomes at matched gestational ages. Microarray analysis identiﬁed
414 probe sets, corresponding to 311 annotated genes differentially
expressed in trisomy 21, only ﬁve of which were physically located on
chromosome 21. Gene set enrichment analysis identiﬁed a single chro-
mosomal band (21q22) containing genes that were up-regulated as a
group. The differentially-regulated genes were analyzed using DAVID
(Database for Annotation, Visualization, and Integrated Discovery).
This functional analysis revealed that oxidative stress, ion transport,
and immune and stress response were the processes that were signiﬁ-
cantly disrupted in fetuses with Down syndrome.
A subsequent study compared cffmRNA from the second-
trimester amniotic ﬂuid supernatant of ﬁve fetuses with trisomy 18
to six gestational-age-matched euploid controls [12]. Hybridization
of mRNA to Affymetrix U133 Plus 2.0 assays revealed 352 probe
sets, corresponding to 251 annotated genes, that were differentially
expressed between trisomy 18 and euploid samples. Only seven of
these differentially expressed genes were actually located on chromo-
some 18. One of the seven genes located on chromosome 18 was
ROCK1, a gene involved in valvuloseptal and endocardial cushion for-
mation. ROCK1was also found to be overexpressed in trisomy 21 [81].
Functional analyses revealed that ion transport, cell-mediated immu-
nity, DNA repair, G-protein mediated signaling, kinase function, and
glycosylation were all disrupted in trisomy 18. Signiﬁcant down-
regulation of genes involved in adrenal development was noted, as
was up-regulation of genes associated with cardiovascular develop-
ment, endocrine function, lipid metabolism, and molecular transport.
4. Cell-free fetal nucleic acids in other maternal body ﬂuids
Cff nucleic acids have been identiﬁed in other maternal bioﬂuids,
such as urine, CSF, and peritoneal ﬂuid. Through isolation of male-
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fetuses, Botezatu et al. found that the human glomerular barrier is
permeable to DNA molecules of sufﬁcient size to be analyzed by
PCR [3]. Shortly thereafter, Al-Yatama et al. demonstrated that nested
PCR ampliﬁcation studies could be used to detect Y-chromosome-
speciﬁc fetal DNA in urine, although the sensitivity and speciﬁcity of
this technique were better for maternal plasma than for urine [4]. In-
vestigation of cffDNA fragmentation patterns in maternal plasma and
urine revealed that fetal DNA fragments in maternal urine are smaller
than those in maternal plasma, providing a potential explanation for
the lower sensitivity and speciﬁcity of detection of cffDNA in mater-
nal urine [31]. Cell-free fetal DNA has also been detected in maternal
CSF and peritoneal ﬂuid. Analysis of CSF from 39 women undergoing
spinal anesthesia in the third trimester found that DYS1 gene se-
quences were detectable in four of 26 samples from women carrying
at least one male fetus and 0 of 13 samples from women carrying
only a female fetus [40]. Cioni et al. reported the detection of Y-
chromosome speciﬁc sequences in the peritoneal ﬂuid of a primigra-
vida undergoing surgical intervention for ovarian torsion at 12 weeks'
gestational age; the patient went on to deliver a male fetus [6].
Makrydimas et al. also identiﬁed cffDNA in peritoneal ﬂuid, reporting
a decrease in concentration of cffDNA from amniotic cavity, to maternal
peritoneal cavity, to maternal serum [74].
5. Clinical applications
5.1. CffDNA in maternal serum and plasma
5.1.1. Fetal sex
First trimester fetal sex determination is important for prenatal di-
agnosis of congenital adrenal hyperplasia (CAH) and for X-linked dis-
orders. Noninvasive early fetal sex determination would limit
unnecessary maternal dexamethasone therapy to reduce masculini-
zation of a female fetus in cases of CAH, and reduce the risk of mis-
carriage associated with invasive prenatal diagnosis for X-linked
disorders [85,86]. Ampliﬁcation of SRY permits accurate identiﬁcation
of fetal gender, although accuracy increases with increasing gesta-
tional age. Individual studies report 80% accuracy of gender identiﬁ-
cation by seven weeks and as high as 100% accuracy by nine weeks
of gestation [86–88]. A study utilizing the deleted in azoospermia
(DAZ) region of the long arm of the Y chromosome demonstrated de-
tection of fetal gender by the ﬁfth week of gestation, with 100% accu-
racy by eight weeks [89]. A recent meta-analysis of 57 selected
studies representing 3524 male-bearing and 3017 female-bearing
pregnancies demonstrated that Y-chromosome-speciﬁc sequences
were detected in maternal blood with 95.4% sensitivity and 98.6%
speciﬁcity overall, with signiﬁcant interstudy heterogeneity. Real-
time quantitative PCR outperformed conventional PCR, and testing
after 20 weeks (sensitivity, 99.0%; speciﬁcity, 99.6%) outperformed
testing prior to 7 weeks (sensitivity, 74.5%; speciﬁcity, 99.1%). Sen-
sitivity and speciﬁcity of testing increased steadily from 7 to
20 weeks. Tests using urine and tests performed before 7 weeks' ges-
tation were unreliable [90]. Direct-to-consumer genetic tests in
which dried maternal blood spots are used to detect fetal Y-speciﬁc
(DYS1) sequences [91] are available to the public in pharmacies and
via the internet without regulation. The accuracy of these tests is un-
known. The ready availability of fetal gender tests has raised impor-
tant ethical considerations [92].
5.1.2. Noninvasive fetal RhD genotyping
Lo et al. were the ﬁrst to describe noninvasive fetal RhD genotyp-
ing using maternal blood. This study demonstrated more reliable di-
agnosis of fetal RhD genotype in the second and third trimesters;
the ﬁrst trimester demonstrated only a 78% concordance rate [93].
Improved real-time PCR (RT-PCR) techniques subsequently increased
the sensitivity of the RhD assay in the ﬁrst trimester to as high as100% [94]. Cardo et al. recently utilized quantitative PCR techniques
to diagnose fetal RhD genotype from ﬁrst trimester maternal plasma
samples, reporting a sensitivity of 100% and speciﬁcity of 93%, with
overall diagnostic accuracy of 97% [95]. False positive cases are most
often due to RhD negative black Africans who actually have an RhD
pseudosequence that is intact but nonfunctional, called RhD ψ, or
a hybrid RHD-CE-Ds gene. RT-PCR ampliﬁcation with specially-
designed sequence-speciﬁc primer pairs has subsequently been
utilized to distinguish RhD from RhD ψ, with reported 99.6–100% ac-
curacy [96,97]. RhD genotyping has been increasingly incorporated
into routine prenatal care in France, Denmark, the Netherlands, and
the United Kingdom, and many believe that this application is now
appropriate for universal clinical application [98].
5.1.3. Single gene disorders
In addition to RhD genotyping, cffDNA has also been utilized in the
prenatal detection of multiple other monogenic disorders. While the
accuracy of RHD DNA detection from maternal plasma approaches
nearly 100%, the noninvasive diagnosis of single gene disorders
characterized by more subtle genetic differences between the mater-
nal and fetal DNA sequences has posed more of a challenge. A
mutation-speciﬁc RT-PCR assay was successfully used to detect the
most common Southeast Asian β-thalassemia mutation in 2002
[99]. However, over 200 β-thalassemia mutations have been de-
scribed, many of which are point mutations [100]. The detection of
single-base differences in fetal DNA with RT-PCR has proven difﬁcult,
due to the lack of absolute speciﬁcity of allele-speciﬁc primers [101]
and the low concentration of fetal DNA in maternal plasma. A
matrix-assisted laser desorption ionization/time-of-ﬂight (MALDI-
TOF) mass spectrometry (MS) method and a single allele base exten-
sion reaction (SABER) MS method have been successfully utilized to
detect paternally-inherited β-thalassemia point mutations in mater-
nal plasma [102]. Li et al. described the use of a peptide nucleic acid
clamp speciﬁc for the maternal allele to suppress unwanted PCR am-
pliﬁcation of this allele, thereby increasing the accuracy of detection
of a paternally-inherited β-thalassemia point mutation [103].
Both digital PCR and gel electrophoresis for size fragmentation of
maternal versus fetal cfDNA have been applied in the NIPD of single
gene disorders. Lun et al. have described the use of a digital PCR-
based relative mutation dosage approach, coupled with a digital
nucleic acid size selection strategy, to enrich fetal DNA for the diagno-
sis of β-thalassemia and hemoglobin E mutations [104]. Tsui et al.
later applied the same digital PCR-based relative mutation dosage ap-
proach to the prenatal diagnosis of an X-linked disorder, hemophilia
[105]. These investigators were able to correctly classify fetal hemo-
philia mutations in 12 maternal plasma samples obtained from 7
hemophilia carriers pregnant with male fetuses. The discovery that
cffDNA fragments are signiﬁcantly smaller than maternally-derived
DNA fragments prompted the utilization of gel electrophoresis to iso-
late these shorter DNA fragments [103,106,107]. This approach has
been successfully employed to diagnose single gene disorders charac-
terized by point mutations, such as achondroplasia [108,109] and β-
thalassemia [103,110,111].
Recent investigations of the use of PCR for NIPD of alpha-
thalassemia, speciﬁcally Hemoglobin Bart's, demonstrated the need
for ongoing research to improve the sensitivity and precision of
these techniques. One investigation failed to reliably diagnose Hemo-
globin Bart's using real-time quantitative PCR [112]. Another investi-
gation utilized qualitative ﬂuorescence PCR to exclude Hemoglobin
Bart's in 10/30 pregnancies, via detection of nondeleted paternally
inherited fetal alleles [113].
The successful diagnosis of Huntington disease via cffDNA in ma-
ternal plasma has been described only in case reports [63,114,115].
It has been found to be more accurate when the fragment of the
IT15 gene containing the CAG repeat is targeted. The indirect analy-
sis, utilizing a polymorphic microsatellite located in exon 1 of the
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rently, the ability to diagnose Huntington disease via maternal
blood is limited to those pregnancies in which the father of the
fetus is affected. The use of allele-speciﬁc PCR to diagnose fetal
conditions in the setting of known paternally-inherited mutations
has also been described for cystic ﬁbrosis [101,116] and myotonic
dystrophy [117].
5.1.4. Non-invasive diagnosis of fetal aneuploidy
The detection of fetal aneuploidy has posed a signiﬁcant techni-
cal challenge compared to the previously described applications be-
cause there is no unique fetal mutation. Prior investigations
demonstrated elevated cffDNA in maternal plasma and serum in
cases of fetal trisomies 21 [32,118,119] and 13, but not in cases of
trisomy 18 [120]. Two studies provided conﬂicting results, ﬁnding
no association between elevated cffDNA levels in maternal plasma/
serum and aneuploidy [118,121]. The promise of an association
between elevated cffDNA and aneuploidy led to the investigation
of second-trimester cffDNA levels as an additional serum screening
marker. Incorporating cffDNA measurements increased the detec-
tion rate for Down syndrome from 81 to 86% when added to the
quadruple screen panel [122].
The use of epigenetic markers is another proposed strategy for
prenatal diagnosis. Epigenetic modiﬁcations are alterations in pheno-
type or gene expression without changes in the actual DNA sequence,
such as DNA methylation [123]. The discovery of differentially
methylated regions (DMRs) between fetal DNA and maternal tissues
provided the basis for an epigenetic approach to prenatal diagnosis
[124]. This approach has the advantage of allowing for the detection
of both maternally and paternally inherited fetal alleles [124]. The
epigenetic–genetic chromosome dosage approach utilizing the puta-
tive promoter of the holocarboxylase synthetase (HLCS) gene on
chromosome 21 was demonstrated to correctly diagnose trisomy 21
in both male and female fetuses [125]. Maspin, the ﬁrst universal
fetal DNAmarker in maternal plasma, is a placental epigenetic marker
that is methylated in maternal leukocytes and hypomethylated in
the placenta [126]. The discovery that maspin, also known as the
SERPINB5 gene (located on chromosome 18) had different methyla-
tion patterns in the placenta compared to maternal blood cells led
to the development of a strategy utilizing epigenetic allelic ratios
to diagnose trisomy 18 in the fetus [66,126]. This discovery
prompted the search for fetal-speciﬁc epigenetic markers on chro-
mosome 21 [127–129]. Of 114 studied genomic regions on chromo-
some 21, 22 DMRs have been identiﬁed [128]. A recent
investigation by Papageorgiou et al. utilized methylated DNA immu-
noprecipitation methodology (MeDiP) and real-time quantitative
PCR to achieve noninvasive prenatal detection of trisomy 21 in 14
cases [130]. The investigators tested methylation ratios for fetal-
speciﬁc DMRs present in maternal peripheral blood and were also
able to correctly diagnose 26 euploid controls. The recently devel-
oped MeDiP technique [131,132] overcomes two of the major limita-
tions of prior techniques employed for epigenetic analysis. There is
no need to use DMRs containing a restriction site, [127,130], nor to
use the methylation-sensitive enzyme sodium bisulfate, which
leads to DNA degradation [133].
The limitations of RT-PCR in detecting aneuploidy have also been
addressed by digital PCR and microﬂuidics [134]. Digital PCR does
not depend on allelic distribution or gender and is able to detect
fetal DNA signals even in the presence of contaminating maternal
DNA or mosaicism. Through the utilization of microﬂuidic valves,
one sample can be divided into hundreds to thousands of individual
reactions, each containing a single template copy. The number of in-
dividual positive PCR reactions is counted and a quantitative assess-
ment of the presence of the target region is made [134,135]. The
thousands of individual reactions facilitate recognition of very small
changes in the amount of DNA, thus permitting the detection of the1.5-fold difference in input DNA concentration occurring in trisomy
21 against a background of abundant maternal DNA transcripts in
maternal plasma [134,136].
Fan and Quake utilized a microﬂuidic chip to examine human ge-
nomic DNA from a trisomy 21 cell line compared to DNA from a nor-
mal cell line [137]. They compared the dosage of an amyloid gene
sequence on chromosome 21 to that of the GAPDH locus on chromo-
some 12 and demonstrated that digital PCR could reliably discrimi-
nate between normal and aneuploid samples, even if aneuploid
material comprised only 10% of the total material examined. This
demonstrated that digital PCR was more precise and sensitive than
RT-PCR or ﬂuorescent QF-PCR (later conﬁrmed by Lun et al. [138]),
and suggested that digital PCR could be suitable for detection of
fetal aneuploidy via cffDNA in maternal blood. The same investiga-
tors later utilized microﬂuidic digital PCR to accurately identify all
cases of fetal trisomy in 24 amniocentesis and 16 chorionic villus
samples [139].
Lo et al. also utilized digital PCR to diagnose aneuploidy via
cffDNA and cffmRNA [136]. They described two digital PCR strategies
for NIPD of fetal aneuploidy. The ﬁrst was based on the PLAC4 mRNA
SNP approach described in Section 2.3.3, and utilized maternal plas-
ma of women carrying fetuses affected with trisomy 21. The second
strategy used a digital relative chromosome dosage approach to
evaluate the dosage of a locus on chromosome 21 compared to a
locus on chromosome 1; this method was able to detect fetal aneu-
ploidy in a mixture of euploid and aneuploid DNA with as low as
25% trisomic DNA.
As digital PCR was being developed, signiﬁcant changes were
occurring in DNA sequencing technology. Massively parallel shotgun
sequencing (MPSS) of cffDNA in maternal plasma, also known as
next-generation sequencing, was ﬁrst described in 2008 by two inde-
pendent reports published two months apart [19,140]. Since those
initial reports, MPSS of cffDNA in maternal plasma has been used to
diagnose trisomies 21, 18 and 13 with high sensitivity and speciﬁcity
in ﬁve independent large clinical trials [141–145].
Chiu et al. were the ﬁrst to attempt to validate the clinical efﬁcacy
and feasibility of MPSS of cffDNA in maternal plasma for diagnosis of
trisomy 21 [145]. These investigators utilized two-plex sequencing to
detect trisomy 21 in 314 plasma samples from high-risk pregnant
women, reporting 100% sensitivity and 97.9% speciﬁcity. An eight-
plex sequencing protocol was tested on 753 maternal plasma sam-
ples, with a 79.1% detection rate of trisomy 21, and 98.9% speciﬁcity.
The authors concluded that the use of MPSS to rule out fetal trisomy
21 would allow pregnant women to avoid 98% of invasive diagnostic
procedures. Ehrich et al. usedMPSS for noninvasive detection of triso-
my 21 in 449 maternal plasma samples, reporting 100% sensitivity
and 99.7% speciﬁcity [141]. Sehnert et al. sought to detect not only
fetal trisomy 21 but also trisomy 18, utilizing MPSS of cffDNA from
119 maternal plasma samples [142]. These investigators reported
100% correct classiﬁcation of trisomy 21 (13 of 13) and trisomy 18
(eight of eight). Chen et al. also utilized MPSS of cffDNA from 392 ma-
ternal plasma samples to evaluate for trisomies 13 and 18 [143].
Using a non-repeat-masked reference human genome and a bioinfor-
matics approach to correct GC content bias, they correctly identiﬁed
25/25 fetuses with trisomy 13 (98.9% speciﬁcity) and 34/37 fetuses
with trisomy 18 (98% speciﬁcity). Although the aforementioned re-
sults were promising, these studies had relatively small sample
sizes, DNA sequencing performed at non-CLIA-certiﬁed laboratories,
and long turnaround time that did not simulate clinical practice.
Palomaki et al. undertook a clinical validation study to overcome
the shortcomings of previous studies [144]. These investigators eval-
uated the ability of next-generation sequencing to identify trisomy 21
in 212 affected pregnancies and 1484 matched euploid controls,
reporting a 98.6% detection rate with a 0.2% false-positive rate. The
same investigators later evaluated the accuracy of MPSS for detection
of trisomies 13 and 18, reporting a detection rate of 100% for trisomy
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0.97%, respectively.
It remains unclear whether MPSS of cffDNA in maternal plasma
can truly be used to diagnose aneuploidy, or whether it should be
used to triage pregnancies at high risk for trisomy 21 for subsequent
invasive diagnostic procedures [145]. The International Society of
Prenatal Diagnosis (ISPD) released a position statement on aneuploi-
dy screening in 2011, stating that “non-invasive approaches to
screening and diagnosis through the analyses of fetal cells or nucleic
acids in maternal circulation…have not yet been validated in clinical
trials and are therefore not ready for clinical use [147].” In a subse-
quent response to Palomaki et al.'s 2011 report, the ISPD released a
rapid response position statement stating that massively parallel se-
quencing of cffDNA in maternal plasma to detect trisomy 21 “consti-
tutes an advanced screening test” and that “conﬁrmation of MPS
positive results through invasive testing would still be required
[148].” Table 1 depicts the availability of noninvasive prenatal diag-
nostic tests using cell-free fetal nucleic acids in the United States,
Europe, and China.
5.1.5. Detection of complications of pregnancy
Given that the placenta is the primary tissue source of circulating
fetal DNA, it is intuitive that changes in cffDNA levels are observed in
abnormal placentation. Elevations in cffDNA have been demonstrated
in cases of placenta previa, accreta, and increta [149,150]. Preeclamp-
sia, another disease associated with abnormal trophoblast invasion, is
also associated with elevated levels of cffDNA in maternal plasma.
Signiﬁcant increases in cffDNA in maternal plasma have been noted
in preeclamptic women compared to normotensive pregnant controls
[151–153]. This increase may precede the development of clinical
symptoms [154,155]. An initial elevation of cffDNA in the plasma
of women who will go on to develop preeclampsia occurs at
17–28 weeks, and a second elevation is noted approximately
3 weeks prior to the onset of clinical symptoms [156]. Maternal DNA
levels are also elevated in women with preeclampsia [157,158]. The
concentration of maternal and fetal DNA in maternal plasma corre-
lates positively with disease severity; women with hemolysis, ele-
vated liver enzymes, and low platelets (HELLP) have higher levels of
cffDNA than preeclamptic women without HELLP. Both have higher
levels than normotensive gestational age-matched controls [158].
The data are conﬂicting on levels of cffDNA in maternal circulation
in cases of fetal intrauterine growth restriction (IUGR). In one study,
abnormal uterine artery Doppler studies and elevated cffDNA levels
in maternal plasma were associated with the development of IUGR
[159]. However, another study comparing plasma of women with
preeclampsia, to that of women with fetuses with IUGR, to that of
gestational age-matched controls, found no increase in cffDNA in
the plasma of pregnant women with fetal IUGR [160]. Elevations inTable 1
Global availability of noninvasive prenatal diagnostic tests using cell-free fetal nucleic acids
Test Status of NIPDa as of early 2012
U.S. Europe
Fetal RhD genotyping (PCR)b Available/CLIAc
Academic and commercial
Available/acad
Fetal sex determination (PCR) Available/DTCd
Not available/CLIA
Available/acad
Fetal aneuploidy (MPSS)e Available/CLIA
Commercial
Available/acad
Array CGHf on amniotic ﬂuid Available/CLIA/academic and commercial Available/acad
a Noninvasive prenatal diagnosis.
b Polymerase chain reaction.
c Clinical Laboratory Improvement Amendments.
d Direct to Consumer.
e Massively parallel shotgun sequencing.
f Comparative genomic hybridization.cffDNA have also been noted in hyperemesis gravidarum [161], poly-
hydramnios [162], and preterm delivery [163], although a recent
study found that cffDNA levels in maternal plasma did not predict
preterm delivery in women with a short cervix at 22–24 weeks [164].
5.2. CffDNA in amniotic ﬂuid
Two studies have investigated utilizing cffDNA in amniotic ﬂuid to
produce a rapid “molecular karyotype.” Larrabee et al. were the ﬁrst
group to utilize fetal DNA from amniotic ﬂuid supernatant for prena-
tal molecular diagnosis [9]. Using cffDNA from 28 amniotic ﬂuid su-
pernatant samples for comparative genomic hybridization (CGH)
microarray analysis, they were able to successfully identify fetal gen-
der, as well as whole-chromosome gains and losses on chromosomes
X and 21. Miura et al. used a targeted microarray-based CGH panel
spotted with bacterial artiﬁcial chromosome (BAC) clones of chromo-
somes 13, 18, 21, X and Y to perform successful molecular karyotyp-
ing for 12 of 13 fetuses within 5 days [10]. One false-negative result
was obtained for a fetus with a balanced translocation. After Lapaire
et al. described technical advances to increase the yield and quality
of cffDNA extracted from amniotic ﬂuid [76], they utilized array
CGH to correctly detect whole chromosome aneuploidy in eight of
nine cases, only missing one case of triploidy [165]. The advantage
of using cffDNA in amniotic ﬂuid compared to DNA from cultured
cells is its turn around time. This technique has already transitioned
to clinical care.
6. Future directions
As a result of advanced parental ages, obesity, and other environ-
mental exposures, infertility and the utilization of assisted reproduc-
tive technologies are becoming increasingly common. NIPD of fetal
aneuploidy is a rapidly evolving area. As of late 2011, MPSS of cffDNA
in maternal plasma is being offered on a commercial basis in China
and the United States. Its clinical role in prenatal screening or diagno-
sis remains to be determined.
The cost and complexity of MPSS may limit its broad implementa-
tion for NIPD of fetal aneuploidy. One disadvantage of MPSS is that it
generates large amounts of unutilized sequencing data. Recent inves-
tigations have tried to address this shortcoming, via selective se-
quencing of cffDNA in maternal plasma. Lo et al. performed a proof-
of-concept study utilizing paired-end MPSS to selectively sequence
SNPs identiﬁed from information about the paternal genotype and
maternal haplotype, in order to construct a genome-wide genetic
map of the fetus [166]. Their ﬁndings suggest that MPSS may be
used to scan the fetal genome for known paternal and maternal poly-
morphisms, enabling targeted and efﬁcient NIPD. Sparks et al. utilized
a novel, highly multiplexed assay called digital analysis of selected.
China
emic Not applicable due to low incidence of RhD negative women
emic Available/commercial
emic and commercial Available/academic and commercial
emic and commercial Available/academic and commercial
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for evaluation of fetal trisomy [167]. Using DANSR assays for loci on
chromosomes 21 and 18, these investigators were able to correctly
classify all cases of T21 (39) and T18 (7) in the 298 pregnant
women studied. Selective sequencing of cffDNA in maternal plasma
takes advantage of the sensitivity of next-generation sequencing,
while improving its efﬁciency and presumably lowering its cost.
While the diagnosis of aneuploidy via next-generation sequencing
has been a recent focus, advances in molecular techniques will likely
allow for greater precision and utilization of NIPD for single-gene
disorders. Another future direction may be the noninvasive prenatal
identiﬁcation of fetal polymorphisms known to be associatedwith com-
plications of pregnancy such as preeclampsia and gestational diabetes.
Two different single nucleotide polymorphisms (SNPs) in the fetal
endoplasmic reticulum aminopeptidase 2 (ERAP2) gene have been
reported to be associated with increased risk for preeclampsia in an
African-American population, a New Zealand/Australian population,
and a Norwegian population [168]. Paternally-inherited fetal polymor-
phisms in the insulin-like growth factor-2 gene (IGF2) were found to
be associated with increased maternal glucose concentrations in preg-
nancy [169]. To date, however, such polymorphisms have primarily
been identiﬁed in neonatal blood rather than via cffDNA in maternal
blood. As more fetal polymorphisms associated with maternal compli-
cations of pregnancy are discovered, identiﬁcation of these polymor-
phisms via cffDNA in maternal plasma may be utilized to help predict
such complications.
Recent work on the fetal transcriptome presents an exciting op-
portunity to do more than diagnose an abnormality; this represents
the ﬁrst opportunity to track fetal development in real-time in both
normal and pathologic states [83]. The unexpected discovery of fetal
brain transcripts in amniotic ﬂuid may facilitate new ways of moni-
toring fetal nervous system development. Comparisons of the normal
second and third trimester amniotic ﬂuid transcriptome to the fetal
mRNA transcriptome present in disease states (both maternal and
fetal) ultimately may allow for the practice of personalized fetal geno-
mic medicine.References
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